Q2 revenue increased 77% globally, including 100% United States sales growth Pipeline of new potential strategic partnerships continues to...
Mauna Kea Technologies Reports Second Quarter and First Half 2023 Revenue
read more
Search Results
Mauna Kea Technologies Announces the Installation of Cellvizio® at University College Cork – APC Microbiome Ireland for Inflammatory Bowel Disease (IBD) Applications
Paris and Boston, July 3, 2023 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the...
Mauna Kea Technologies: release of the 2022 Universal Registration Document
Paris and Boston, June 30, 2023 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the...
Mauna Kea Technologies Announces the Appointment of Côme de La Tour du Pin as its Chief Financial Officer
Paris and Boston, June 13, 2023 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the...
Mauna Kea Technologies Announces the Launch of the Transfer of its Shares to Euronext Growth Paris
Paris and Boston, June 8, 2023 – 5:45 PM CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the...
Mauna Kea Technologies Announces Results of its 2023 Ordinary and Extraordinary Annual General Meeting
Shareholders approved all proposed resolutions Paris and Boston, June 5, 2023 - 5:45 pm CEST - Mauna Kea Technologies (Euronext: MKEA)...
Mauna Kea Technologies Announces Start of Enrollment in Peripheral Lung Cancer Multi-Site Clinical Trial Combining Ion® with Cellvizio®
Study will advance the validation of Cellvizio® as a real-time biopsy guidance tool during robotic-assisted bronchoscopy Paris and Boston,...
Mauna Kea Technologies secures an equity line financing with Vester Finance limited to a maximum of 11.4% of the capital
Cash position of €6.7m at May 31, 2023 strengthened by USD 2.5m received from the joint venture with Tasly Pharmaceutical Paris and...
Proposed transfer of the listing of Mauna Kea Technologies’ shares to the Euronext Growth Paris market
Paris, April 26, 2023 - 5:45 p.m. CEST - At its meeting of April 5, 2023, the Board of Directors of Mauna Kea Technologies (Euronext...
Mauna Kea Technologies Announces Sales of €4.2 million for the first quarter of 2023, up 121% from 2022
Recognition of first revenues from the Joint Venture with Tasly Pharmaceutical Paris and Boston, April 20, 2023 - 5:45 p.m. CEST - Mauna...
Mauna Kea Technologies Reports 2022 Annual Results
2022 sales in line with expectations at €7.5 million Maintained a stable gross margin at 73% with reduced 2022 operating loss Cash...
Mauna Kea Technologies announces the coverage of its stock by Portzamparc – Groupe BNP Paribas
Mauna Kea Technologies today announces the coverage of its stock by Portzamparc – Groupe BNP Paribas. Portzamparc – Groupe BNP...